Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in previously treated CLL/SLL: Updated results from the phase 1/2 BRUIN study Meeting Abstract
| Authors: | Coombs, C. C.; Pagel, J. M.; Shah, N. N.; Lamanna, N.; Munir, T.; Lech-Maranda, E.; Eyre, T. A.; Woyach, J. A.; Wierda, W. G.; Cheah, C. Y.; Cohen, J. B.; Roeker, L. E.; Patel, M. R.; Fakhri, B.; Barve, M. A.; Tam, C. S.; Lewis, D.; Gerson, J. N.; Alencar, A.; Ujjani, C.; Flinn, I.; Sundaram, S.; Ma, S.; Jagadeesh, D.; Rhodes, J.; Taylor, J.; Abdel-Wahab, O.; Ghia, P.; Schuster, S. J.; Wang, D.; Nair, B.; Zhu, E.; Tsai, D. E.; Davids, M. S.; Brown, J. R.; Jurczak, W.; Mato, A. R. |
| Abstract Title: | Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in previously treated CLL/SLL: Updated results from the phase 1/2 BRUIN study |
| Meeting Title: | 10th Annual Meeting of the Society of Hematologic Oncology (SOHO) |
| Keywords: | clinical trial; cll; chronic lymphocytic leukemia; phase i/ii; pirtobrutinib; btki |
| Journal Title: | Clinical Lymphoma, Myeloma and Leukemia |
| Volume: | 22 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2022 Sep 28-Oct 1 |
| Meeting Location: | Houston, TX |
| ISSN: | 2152-2650 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2022-10-01 |
| Start Page: | S268 |
| End Page: | S269 |
| Language: | English |
| ACCESSION: | WOS:000897948100206 |
| PROVIDER: | wos |
| DOI: | 10.1016/s2152-2650(22)01327-1 |
| Notes: | Meeting Abstract: CLL-120 -- Source: Wos |
